- Goldman upgraded Yum! Brands (NYSE: YUM) to Buy from Neutral on expectations business in the U.S. and China will improve in the second half of 2009. Goldman raised its target price on shares to $40 from $36.
- Canaccord upgraded Exco Resources (NYSE: XCO) to Buy from Speculative Buy citing the company's financial transactions to reduce debt. The firm, which has a $17 target on the stock, says Exco now has a stronger balance sheet, a greater geographic focus, and the ability to expedite drilling programs.
- ThinkEquity upgraded Shanda (NASDAQ: SNDA) to Accumulate from Source of Funds and raised its target to $60 from $50. The firm believes recent weakness on regulatory concerns is overdone and that Q2 estimates are conservative.
- Mack-Cali Realty (NYSE: CLI) was upgraded to Overweight from Equal Weight at Barclays.
- Marvel Entertainment (NYSE: MVL) was upgraded to Overweight from Neutral at JPMorgan.
- France Telecom (NYSE: FTE) was upgraded to Outperform from Underperform at Credit Suisse.
PVSW posts
FeedAnalyst upgrades, downgrades and initiations: HOT, MVL, NDAQ, PALM, YUM ...
Continue reading Analyst upgrades, downgrades and initiations: HOT, MVL, NDAQ, PALM, YUM ...
Analyst initiations: Syntroleum, Pervasive Software, Ardea Biosciences
MOST NOTEWORTHY: Syntroleum, Pervasive Software and Ardea Biosciences were today's noteworthy initiations:- Merrriman believes Syntroleum (NASDAQ: SYNM) possesses the technological platforms with its Biofining process and the cost structures with its Tyson Foods (NYSE: TSN) relationship needed to commercialize clean synthetic fuels. The firm started shares with a Buy rating.
- Pervasive Software (NASDAQ: PVSW) was assumed with a Buy rating and $7 target at B. Riley, as they find shares attractive in this market given the company's solid balance sheet with a sizeable cash balance and positive operating cash flow. They believe the stock is undervalued at current levels.
- Ardea Biosciences (NASDAQ: RDEA) was assumed with an Outperform rating at Cowen. The firm believes Ardea has a promising clinical pipeline for HIV, gout, and cancer.




